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Abstract 
The effects of iPLA2β (Ca
2+-independent Phospholipase A2β) and MMP-9 (Matrix 
Metalloproteinase-9) have been a recent focus of research in the progression of cancer 
cell proliferation and migration. However, their roles are not entirely known, especially 
concerning nicotine-induced breast cancer cell advancement. The purpose of this study 
was to determine the involvement of iPLA2β in nicotine-induced breast cancer cell 
proliferation. BEL (bromoenol lactone), a suicide inhibitor of iPLA2β, was hypothesized 
to attenuate nicotine-induced breast cancer cell proliferation and tumor growth. 
Following the BEL treatment, the in-vitro results exhibited a significant decrease in 4T1 
cell proliferation for both basal and nicotine-induced, as shown by MTT proliferation 
assays. Scratch and transwell assays revealed migration was also significantly attenuated. 
In addition, the expression of MMP-9 was discovered to have expressed in an iPLA2β-
dependent manner, which further supports the idea that iPLA2β plays a significant role, 
concerning the mediation of basal and nicotine-induced cancer cell progression. Our in-
vivo results also supported this conclusion. In mice, basal and nicotine-induced tumor 
growth was significantly decreased, in comparison with the control group. The presence 
of nicotine-induced tumors in lung tissue was reduced significantly. In-vitro and in-vivo 
results suggest that iPLA2β plays a critical role in the regulation of breast cancer cell 
proliferation and migration and is found upstream of MMP-9. In addition, nicotine-
induced breast cancer is promoted through iPLA2β expression. Because BEL was found 
to reduce the effects of this, it may be a possible chemotherapeutic drug to clinically 
develop.   Keywords: iPLA2β, MMP-9, BEL, proliferation, migration, metastasis 
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Introduction  
According to the American Cancer Society (2016), there is an estimated 246,660 new 
cases of breast cancer for 2016, with 40,450 deaths in the United States. At an occurrence 
of 29% out of all cancers, breast cancer is most common type of cancer found in women. 
Stage IV breast cancer is the most invasive. At this stage, metastasis has occurred, which 
means that tumors have spread to other parts of the body (American Cancer Society, 
2016). There is an increased risk of mortality as cancer spreads. For breast cancer, there 
is a 99% survival rate for local breast cancer compared to a 26% survival rate for distant, 
which means metastasis has occurred (American Cancer Society, 2016.  
It has been found that cigarette smoke increases the risk of getting breast cancer. 
In a cohort study, it was found that the rate of new cases of breast cancer was higher in 
smokers than in non-smokers (Simon, 2013).  Cigarette smoke has been linked to an 
increase in the overall invasiveness of breast cancer, including an increase in anchorage-
independent growth, increased motility, and fibroblastoid morphology. Therefore, 
cigarette smoke contributes to the metastatic ability of breast cancer cells (Simon, 2013). 
The FDA (2012) has identified many HPHC’s (Harmful and Potentially Harmful 
Constituents) in cigarette smoke. These include carcinogens, respiratory toxicants, 
cardiovascular toxicants, reproductive or developmental toxicants, and addictive 
components, which add up to 93 identified harmful components, 78 of which are 
carcinogens.  
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Nicotine, in particular, has been shown to stimulate apoptosis resistance of breast 
cancer cells, which would enhance proliferation, leading to tumor growth (Guha, et al., 
2014). In addition, nicotine is very nonpolar, which allows for its ability to diffuse 
through the lipid bilayer of cells, without the use of a carrier protein. This gives nicotine 
the potential to enter all cells. Though nicotine has been linked with increased 
progression of breast cancer, the pathways involved nicotine-induced breast cancer cell 
proliferation and migration are still unknown.  
The enzyme iPLA2β has been identified as a contributor to different cancer types, 
including prostate and ovarian cancers. It is involved in the proliferation and migration of 
ovarian cancer cells (Li et al., 2014) and the survival of prostate cancer cells (Nicotera et 
al., 2009). It is found in the cytosol and membranes and is a member of the iPLA2 family 
of enzymes. One of its major functions is to maintain membrane homeostasis by 
degrading phospholipids. The enzyme hydrolyzes at the sn-2 position, releasing 
arachidonic acid, which leads to a variety of outcomes, including inflammation (Akiba & 
Sato, 2004). iPLA2β is associated with cancer, among other disease states. Upregulation 
of iPLA2β has been connected with hypertension (Calderon et al., 2012) and it is 
hypothesized that the regulation of iPLA2β may be effective against β-cell dysfunction 
related to diabetes (Lei, Zhang, Bohrer, Barbour, & Ramanadham, 2012). In addition, 
iPLA2β is linked with alzheimer’s (Talib, Hototian, Joaquim, Forlenza, & Gattaz, 2015).  
 MMP-9 (Matrix Metalloproteinase 9) contributes to tumor vascularization and 
growth and is known to be involved in the metastasis of breast cancer. MMP’s break 
down basement membranes, which allows cancerous cells to get into the blood stream 
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(Mehner, et al., 2014). Both iPLA2β and MMP-9 play roles in the progression of breast 
cancer, and may be in the same cell signaling cascade.  
          In this study, Bromoenol Lactone (BEL) was examined to be a chemotherapeutic 
agent. BEL is an irreversible inhibitor, specific to iPLA2β (Jenkins, Han, Mancuso, & 
Gross, 2002) and has been used in order to stimulate apoptosis (Fuentes, Perez, Nieto, 
Balsinde, & Balboa, 2003). In this study, the effects of nicotine on iPLA2β were 
observed, as well as the link between iPLA2β and MMP-9, as well as the results of BEL 
administration. The cell signaling cascade related to iPLA2β may be effective in 
providing a new proposal for an effective chemotherapeutic treatment.  
Methods 
(Referring to our paper “Bromoenol Lactone Attenuates Nicotine-
Induced Breast Cancer Cell Proliferation and Migration”) 
Cell Culture 
A GFP (Green Flourescent Protein) labeled 4T1 mouse mammary tumor cell line 
was used, which was a donation from Dr. Shu Liu and Dr. Kai Su; this was originally 
from ATCC. Dulbecco’s Modified Eagle Medium (DMEM) was used to culture the cell 
line, with the addition of 100U/ml penicillin, 100µg/ml streptomycin, and 10% (vol/vol) 
Fetal Bovine Serum. These cultures remained incubated at 37o C, with 95% air and 5% 
CO2.  
Animals 
Ten-week-old female BALB/c mice were obtained from Jackson Laboratory 
(BarHarbor, ME). The mice were on exposed to 12 hour light and dark periods and fed 
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standard rodent chow (Prolab ISOPRO RMH 3000Irradiated LabDiet; Purina Mills 
International). They were given one week to habituate. The committee on animal research 
care and use at Eastern Kentucky University approved the protocols used.  
In-Vivo Xenograft Model of Breast Cancer and Drug Delivery 
DMEM (100µl) without FBS was used to suspend 1x105 tumor cells, which was 
injected into the right mammary fat pad of the mice. Following anesthetization with 
gaseous isoflourane mixed with O2 (3–5% isoflurane/97% O2), mini-osmotic pumps 
(Alzet model 2004, 28-day release, Alza Co., Palo Alto, CA) were inserted 
subcutaneously via a scapular region incision onto the right flank. The pumps contained 
either Nicotine (Sigma-Aldrich [5 mg/kg/day]) or Saline (50% DMSO). Throughout the 
procedure, the mice were kept under using isoflurane missed with O2  (1–2% 
isoflurane/97% O2). A Drager 19.1 model isoflurane machine (Highland Medical 
Equipment) was used for anesthetization. Intraperitoneal injections of either BEL 
(Bromoenol Lactone), [Cayman Chemical Company, lot 70700; (10 ug/g/day)] or saline 
was given daily. Tumor volumes (mm3) were found using the equation (width)2 × 
length/2, in order to measure the tumor growth; width was the smaller measurement. The 
mice were put down after 2 weeks, and tumor volume and weight were recorded. Tissues 
were isolated and mounted or formalin fixed. Mounting was accomplished using Optimal 
Cutting Temperature compound (OCT; Tissue Tek, Torrance, CA).  
Histological and Immunohistochemical Staining 
Paraffin-embedded tissues were cut 5 µm thick and were deparaffinized with 
xylene. They were then rehydrated, followed by immuhistochemistry procedures as 
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previously described (Liu et al., 2013). Slides were incubated at 4oC with primary 
antibodies. These antibodies included iPLA2β β (1:100, donation from Dr. Guo 
University of Kentucky), MMP-9 (1:500, Cell Signaling), MMP-2 (1:500, IHC World), 
and GFP (1:500, Cell Signaling). Counterstaining was done using hematoxylin and 
mounted on slides using paramount; Hematoxylin and Eosin (Surgipath) were used to 
stain lung and liver stains. An Olympus IX70 microscope equipped with Olympus DP70 
digital camera was used to magnify the images 20 to 40x. An Olympus digital camera 
with Olympus MicroSuit-B3 Software was used to analyze large tumor areas.  
Cell Proliferation 
A cell count assay was performed, which aided in predicting the lowest nicotine 
concentration that would produce cell proliferation. Cells (1x104) were spread on 6 well 
plates, and media was added, which contained 10% FBS. Either DMSO (control) or 
Nicotine (1uM, 5μM, or 10μM) was added to the plates. All in-vitro experiments utilized 
S-BEL (Cayman Chemical Company, 10006801). The cells were left to grow for 24, 48, 
and 72 hours. This was followed by trypsinization and suspension with typhan blue. The 
cells were then counted using a hemocytometer, which was useful for analyzing the 
degree of proliferation.  
An MTT assay was used to determine the potentiality of BEL reducing the 
nicotine-induced cell proliferation. Cells (500 cells/µl) were spread in a 96-well plate, 
followed by the addition of DMSO (control), 10 μm Nicotine, 3 μm BEL, or both BEL 
and Nicotine, which was repeated after 24 hours. After 48 hours, MTT solution (10 µl) 
from Vbrant MTT Cell proliferation assay kit (Life Technologies) was used for the 
incubation of the cells (37oC for 4 hours). Cells were solubilized, mixed with SDS 
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(sodium dodecyl sulfate), and a Phenix Genios Tecon 96 well plate reader was used to 
read the absorbance at 595 nm.  
Cell Migration 
A scratch/wound healing assay and transwell assay were performed. A 6-well 
plate was used for cell culturing for the scratch assay. Culturing continued until a 
confluent monolayer arose. The wells were scratched using a 20 µl pipet tip. PBS was 
used to rinse the wells in a sequential fashion, and the wells were cultured in DMEM 
with 10% FBS. DMSO (control), 10μmNicotine, 3 μm BEL or both BEL and Nicotine 
were added to the wells. At 0, 6, and 24 hours, four images (10x) were taken. Three 
leading edge measurements were used to find the gap width. 
 Three μm BEL (30 minutes pretreatment), 10μm Nicotine, both BEL and 
Nicotine, or DMSO (control) were used to treat cells (1x105) for the transwell assay as 
well. Using DMEM with 0.1% FBS, cells were spread in the upper insert (8-μm pore; 
corning), and 10% FBS was in the fitted culture dishes; the cells were left for 4 hours. 
The chambers and plates were separated, the chambers were fixed, and the cells that 
migrated were stained with DAPI. Four images were taken of each well (20x).  
Gel Zymography 
 Parallel gel zymography experiments were used in order to determine which 
MMP (matrix metalloproteinase) is the most prominently secreted due to nicotine 
treatment. Serum was not added to the culture medium during these experiments. The 
experiments were performed following 24 hours of cell starvation. No MMPs were found 
in the culture medium. Ten µl of culture medium was tested after the previously 
described treatment for 24 hours of 1x106 cells. Samples were stained with GelCode Blue 
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Phalloidin (Life Technologies, Grand Island, NY) following the addition of native Tris-
Glycine with 0.15% gelatin and incubation with reaction buffer. ImageJ software was 
used to analyze the sample band densities. 
In situ Zymography 
The MMP-9 secreted due to nicotine treatment was analyzed. The 4T1 cells 
(1x104) were placed on cover slides, starved for 24 hours, and treated as previously 
described for 24 hours. The procedure was performed as described previously (Liu et al., 
2013), and the cells were counterstained with DAPI following incubation with MMP-9 
(1:500, Cell Signaling). 
Statistics 
Data was pooled and described as mean ±SEM. GraphPad, Prism 6 (San Diego, 
CA) was used for statistical analyses, and T-tests with one- and two-way ANOVAs were 
utilized.  
Results 
(Referring to our paper “Bromoenol Lactone Attenuates Nicotine-
Induced Breast Cancer Cell Proliferation and Migration”) 
 
Nicotine-induced cell proliferation and migration is attenuated by BEL 
  Different concentrations of nicotine were administered to the breast cancer cells. 
At 10 µM, which was the highest concentration, the cell proliferation increased 
significantly (Figure 1A). The MMT assay exhibited that—in the presence of BEL—the 
cell proliferation was diminished, both with nicotine and without nicotine treatment 
(Figure 1B).   
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 Not only did BEL reduce breast cancer cell proliferation, but it was also found to 
be effective in reducing the migration of breast cancer cells—even the cells that were 
treated with nicotine. This was shown in the scratch assays (Figure 2A-B). A transwell 
assay was conducted in order to confirm the ability of BEL to reduce breast cancer cell 
migration. Again, BEL was found to reduce breast cancer cell migration—both basal and 
nicotine-induced (Figure 2C-D). Due to the role of BEL—as a suicide inhibitor of 
iPLA2β—the results are indicative of iPLA2β being a contributor to breast cancer cell 
proliferation and migration, both basal and nicotine-induced.  
MMP-9 expression and secretion is decreased by BEL 
  In order to examine the effects of iPLA2β on metastasis, gel zymography 
experiments were performed to find the type of MMP produced as a consequence of 
nicotine treatment. The particular MMP found to be increased was MMP-9, and its 
expression was reduced by BEL (Figures 3A-C).  
 The amount of iPLA2β exhibited in breast cancer tumor tissue and normal 
mammary tissue was examined; there was an upregulation in the tumor tissue (Figure 4). 
An upregulation of MMP-9 in tumor tissue was also discovered through GFP staining. 
This association points to a link between iPLA2β and MMP-9—it appears that iPLA2β 
results in MMP-9 production in tumor tissue. This would mean that iPLA2β may be a 
promotor of metastasis in stage IV breast cancer.  
Nicotine-induced breast cancer tumor growth is attenuated by BEL  
  The 4T1 breast cancer cells produced tumors, which were grown in the mice—
some with nicotine and some without. BEL injections were given daily, and tumor size 
was continually monitored. The nicotine-treated tumor growth and basal tumor growth 
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were both attenuated by BEL (Figure 5A). The liver was also examined, specifically 
weight and cytotoxicity, in order to see if there were any major physiological side effects 
due to BEL treatment; no differences in liver tissue were observed (Figure 5B-C).  
Nicotine-induced metastasis is decreased by BEL 
 The effects of nicotine on breast cancer metastasis was examined through tissue 
immunohistochemistry. The tumor tissue exhibited an upregulation of iPLA2β in the 
presence of nicotine, and BEL reduced this upregulation, for both basal and nicotine-
induced (Figure 6). In addition, there was also an upregulation of MMP-9 in tumor tissue; 
this was also reduced by BEL—both basal and nicotine-induced (Figure 6). The results 
point to a link between nicotine and the upregulation of iPLA2β and MMP-9, which leads 
to an increase in metastasis.  
 Nicotine was found to upregulate HIF-1 alpha (Figure 6) and CD31 (Figure 7) in 
tumor tissue, which was decreased through BEL treatment. In hypoxic tumor tissue, 
angiolytic factor production and blood vessel formation are increased. The upregulation 
of HIF-1 expression suggests that nicotine increases tumor hypoxia conditions (Figure 6). 
The increase in endothelial cells in the tissue is suggestive of angiogenesis. These results 
support the idea that nicotine can promote metastasis by giving breast cancer cells access 
to 
 The data indicated that nicotine promotes metastasis. The lung tissue was 
analyzed, and this conclusion was further supported. There was a significant increase in 
nicotine-induced breast cancer tumor colonization, compared to basal tumor colonization 
(Figure 8). BEL not only attenuated nicotine-induced tumor formation, but basal as well. 
This was shown through HE staining and GFP cells (Figure 8). The area analysis of the 
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lung sections further verified the attenuation of nicotine-induced tumor colonization by 
BEL (Figure 9).  
Discussion 
Cigarette smoke has been shown to contribute to the progression of breast cancer 
through mediating cell proliferation and metastasis. However, the pathways related to this 
enhancement are unknown. Research has found iPLA2β to play a role in cancer 
development. In this study, iPLA2β was shown to be linked to nicotine-induced breast 
cancer progression. The cell proliferation and migration, enhanced by nicotine, occurred 
in an iPLA2β dependent manner. Our  data exhibited that blocking iPLA2β can be 
effective against stage IV breast cancer, as well as stage IV nicotine-induced breast 
cancer. Bromoenol lactone was able to reduce tumor growth in both control and nicotine-
induced breast cancer. In addition, BEL treatment kept metastasis from occurring in the 
lung tissue. There was not only a reduction of iPLA2β with BEL treatment, but MMP-9—
a contributor to metastasis—as well. Because BEL is an inhibitor specific to iPLA2β, this 
suggests that these two enzymes are linked in a cell signaling cascade that promotes the 
progression of breast cancer—control and nicotine-induced. The effectiveness against 
stage IV breast cancer progression—including proliferation, migration, and metastasis—
suggests that BEL would also be effective against early stages of breast cancer. 
Furthermore, there was no cytotoxicity found in the liver, which means there are no 
apparent severe side effects. The data shows that iPLA2β mediates the production of 
MMP-9, both of which are enhanced with nicotine. In conclusion, bromoenol lactone was 
able to greatly reduce the production of these enzymes, leading to decreased tumor size 
and metastasis, with no toxicity.  
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Figures 
(Obtained from “Bromoenol Lactone Attenuates Nicotine-Induced 
Breast Cancer Cell Proliferation and Migration”) 
 
 
Fig 1. Nicotine-induced Cell Proliferation is attenuated by BEL. 
 
Promotion of 4T1 cell proliferation by nicotine dose dependently (1, 5, 10μM) was 
analyzed by cell count analysis for time intervals indicated above. Control wells were 
treated with DMSO (A). Cells were treated with nicotine (10μM) in the presence or 
absence of BEL (3μM) and proliferation measured by MTT assay (B). (n = 6–7). *, 
p<0.05 **, p<0.01 ***, p<0.00; two and one-way ANOVA. 
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Fig 2. Nicotine-induced Cell Migration is decreased by BEL. 
 
Cultured 4T1 cells were scratched under normal conditions (DMSO) and nicotine (10μM) 
in the presence or absence of BEL (3μM). Representative 10x images of scratch 
migration assay, indicating BEL treatment attenuated nicotine induced migration (A). 
Cell migration was quantitatively evaluated by measuring the distance between the 
scratch edges after 6, 24, and 48 hr (B). Representative images of Boyden chamber 
migration assay, cells were treated with nicotine (10M) in the presence or absence of 
BEL (3μM, 30 minute pretreatment) for 4 hr (C). Cell migration was quantitatively 
evaluated by counting the number of cells migrated (D). (n = 3–5). *, p<0.05 **,p<0.01; 
one-way ANOVA. 
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Fig 3. BEL decreases Nicotine-induced MMP-9 Expression and Secretion. 
 
An In-situ zymography was conducted with cells treated dose dependently with nicotine 
(1, 5, 10μM) in the presence or absence of BEL (3μM) for 24 hr. Cells were stained with 
MMP-9, phalloidin, and DAPI (A). Cell culture media was isolated from cells treated as 
previously described and a gel zymography was performed; the gel molecular weight 
standard from top to bottom is 103kDa, 77kDa, 49kDa, 34kDa, and 28kDa. A 
representative image of gel zymography shows a band corresponding to the molecular 
weight of proMMP-9 (92kDa) (B) and the area of gelatin dissolved was quantified (C). n 
= 3, *,p<0.05. ***, p<0.001; one-way ANOVA. 
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Fig 4. iPLA2β and MMP-9 Expression is upregulated in 4T1 tumor tissue. 
 
Normal mammary or 4T1 tumor tissue grown for 2wks in 12wk old Female BALB/c 
mice were isolated and embedded in paraffin. Tissue sections were stained with anti-GFP 
(green-fluorescent protein), iPLA2β, or MMP-9 antibodies. Positive staining is indicated 
by dark brown coloration and representative images shown. 
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Fig 5. Nicotine-induced Tumor Growth is decreased by BEL. 
 
Female BALB/c mice were implanted with 4T1 cells (1X105) in the right second 
mammary fat pad. Tumors were grown for 2wks in mice infused either with nicotine 
(5mg/kg/day) or saline (50% DMSO) and in the presence or absence of BEL 
(10ug/g/day). Tumors were isolated and final tumor volume (A) and liver weight (B) 
measured. Liver cytotoxicity was analyzed by HE staining with representative 10x and 
20x images shown (C) (n = 8). *, p<0.05 **, p<0.01; unpaired t-test. 
 
. 
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Fig 6. Nicotine-induced iPLA2β and MMP-9 Expression in Tumor Tissue is 
decreased by BEL. 
 
Control versus BEL and Nicotine versus Nicotine plus BE (n = 4): 4T1 tumor tissue 
grown for 2wks in 12wk old Female BALB/c mice were isolated and embedded in 
paraffin. Tissue sections were stained with anti-iPLA2β, MMP-9, MMP-2, and HIF-
1alpha antibodies. Positive staining is indicated by dark brown coloration and 
representative images shown. 
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Fig 7. Nicotine-induced CD31 is decreased by BEL. 
 
Isolated tumor tissue was embedded in OCT and stained with CD31 and counterstained 
with DAPI. Representative images are shown. n = 4. 
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Fig 8. Nicotine-induced breast cancer metastasis in lung tissue was attenuated by 
BEL. 
 
Lungs were isolated and representative 10x images of tumor colonization shown by HE 
and GFP staining. 
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Fig 9. Nicotine-induced breast cancer metastasis in lung tissue was attenuated by 
BEL. 
 
Tumor area (μm2) was quantified in the lung sections stained with HE. n = 4, **, p<0.01; 
one-way ANOVA. 
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Figure 1A: Nicotine-induced cell proliferation (Cell Count analysis) 
 
 
 
 
Column1 Control BEL Nicotine Nicotine + 
BEL 
Trial 1 7.3 4.6 17.3 2.5 
Trial 2 10 3.75 11.6 4.5 
Trial 3 16.25 6.5 23.75 4 
Trial 4 9.75 6.75 24.25 5.25 
Trial 5 11 3.5 9.3 1.5 
Trial 6 7.4 1.3 
  
Trial 7 8 1.25 
  
 
Figure 1B: BEL attenuates nicotine-induced cell proliferation (MTT assay) 
 
 
 
 
Column1 Contr
ol 
10mM 
Nic 
10mM 
Nic + 
BEL 
BEL CTR
L 
10m
M 
Nic2 
10mM 
Nic + 
BEL3 
BEL4 
Trial 1 74.3 50 75.5 74.9 39.4 20 59.14 52.3 
Trial 2 72 67.9 84.8 84.09 0.045 0.04 45 45.7 
Trial 3 73.8 70 91.65 94.2 28.8 10.7 51.81 59 
Trial 4 66.2 65.1 82.13 90 37 0.116 0.0007 82 
Trial 5 77.9 61.8 83.4 79.4 
    
Trial 6 83.2 58.15 86.39 84.3 
    
 
Figure 2A: Nicotine-induced cell migration is attenuated by BEL (Scratch assay) 
 
Column1 Control BEL Nicotine Nicotine + 
BEL 
Trial 1 10 4.6 17.3 2.5 
Trial 2 7.3 3.75 11.6 4.5 
Trial 3 16.25 6.5 23.75 4 
Trial 4 9.75 6.75 24.25 5.25 
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Trial 5 11 3.5 9.3 1.5 
Trial 6 7.4 1.3 
  
Trial 7 8 1.25 
  
 
Figure 2B: Nicotine-induced cell migration is attenuated by BEL (Transwell Assay) 
 
 
 
Column1 Trial 1 Trial 2 Trial 3 
Control 32.75 21.81 33.58 
1μM Nicotine 38.18 38.88 37.08 
5μM Nicotine 46.21 31.81 39.59 
10μM Nicotine 46.33 43.52 40.39 
BEL 35.53 34.92 28.66 
1μM Nicotine + 
BEL 
26.49 32.03 25.46 
5μM Nicotine + 
BEL 
20.51 32.5 21.87 
10μM Nicotine + 
BEL 
13.03 4.49 18.84 
 
Figure 3C: Nicotine-induced MMP-9 secretion is attenuate by BEL (Gel 
Zymography) 
 
 
Control BEL  Nicotine Nicotine + BEL 
0.00116 0.00102 0.00119 0.00049 
0.00298 0.0012 0.0065 0.00018 
0.000745 0.00027 0.0026 0.00201 
0.0023 0.000078 0.00616 0.00034 
0.00088 0.00096 0.00214 0.000155 
0.00063 0.00013 0.00265 0.00027 
0.0035 0.000545 0.0123 0.0011 
0.0013 0.00008 0.00557 
 
0.00016 
   
 
Figure 5A: Tumor Volume to Body Weight 
 
 
 
Control BEL Nicotine  Nicotine + BEL 
0.064 0.051 0.071 0.056 
0.056 0.055 0.055 0.057 
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0.0544 0.058 0.064 0.0821 
0.0633 0.058 0.059 0.055 
0.056 0.053 0.053 0.052 
0.06 0.063 0.053 0.06 
0.054 0.059 0.057 0.055 
0.0522 
 
0.0619 
 
 
 
Figure 5B: Liver Weight to Body Weight 
 
 
Control BEL Nicotine Nicotine + BEL 
1400.83 0 8597.29 0 
868.65 0 9472.54 0 
397.99 0 6351.36 0 
693.6 0 2814.02 0 
394.69 
 
1667.93 
 
946.26 
 
5649.5 
 
873.6 
 
4150.01 
 
  
19440.5 
 
  
7167.16 
 
  
1193.98 
 
  
4772.6 
 
 
Figure 8B: Nicotine-induced lung tumor area µm2 
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